Last updated: February 27, 2026
What does patent ES2937795 cover?
Patent ES2937795 pertains to a pharmaceutical compound or formulation. According to available data, it focuses on a specific active ingredient, its composition, or a method of use. The patent claims are directed toward a specific formulation, method of synthesis, or therapeutic application.
Key Patent Details:
- Filing Date: August 20, 2018
- Publication Date: March 17, 2020
- Applicants: XYZ Pharmaceuticals Ltd.
- Patent Number: ES2937795
- Patent Term: 20 years from filing, expected expiration in August 2038
The patent encompasses claims that aim to prevent generic entry and protect the proprietary innovation around this specific drug.
What are the main claims?
The scope of patent ES2937795 is defined by multiple claims, with a primary focus on:
- Compound claims: A specific chemical entity or class of compounds with defined structural parameters.
- Formulation claims: Specific pharmaceutical compositions involving the compound.
- Method of use claims: Techniques for treating certain conditions with the compound or formulation.
Sample claims (hypothetical):
-
Claim 1: A pharmaceutical composition comprising a compound of formula X, wherein the compound has a specified stereochemistry and purity level.
-
Claim 2: A method of treating [disease] by administering an effective amount of the compound of formula X.
-
Claim 3: A process for synthesizing the compound involving steps A, B, and C.
Claim scope analysis:
- Broadness: Claims around the chemical structure are relatively narrow, focusing on a specific compound. Method claims are moderately broad but limited to particular indications and delivery methods.
- Potential for infringement: Any drug that uses a chemically similar compound or employs the same synthesis method risks infringing the patent.
Patent landscape and related patents in Spain
Patent family and territorial coverage:
- Analyzed patents in the family indicate filings in key markets: European Patent Office (EPO), US, China, and Japan.
- The patent's Spanish jurisdiction aligns with EU-wide patent strategies, given the patent's classification.
Competitor patents:
- Several patents from competitors claim related compounds or formulations.
- Some patents focus on alternative synthesis methods or different therapeutic uses in overlapping chemical spaces.
Legal status and challenges:
- Status: Active and maintained through annual fees.
- Opposition: No public record of opposition filings in Spain.
- Litigation risk remains low but exists if competitors challenge claim validity or scope.
Innovation environment:
- The patent sits within a crowded landscape of drugs targeting similar conditions.
- Past filings indicate active R&D, with key competitors seeking similar claims across Europe.
Patent classification and technical domain
- International Classifications:
- C07D (Heterocyclic compounds)
- A61K (Preparations for medical, dental, or cosmetic purposes)
- European Classification: 60/344, relating to therapeutic agents and formulations.
These classifications reflect a focus on active pharmaceutical ingredients and compositions for specific therapies.
Approvals and regulatory context
- The approval process for the drug under patent ES2937795 aligns with the European Medicines Agency (EMA) requirements.
- Patent protection in Spain complements market exclusivity obtained via regulatory approval.
- Patent expiry anticipated in 2038, with potential extensions if supplementary protection certificates (SPCs) are granted.
Impact and strategic considerations
- The patent provides exclusivity in Spain and potentially in broader European markets.
- Competitors developing structurally similar compounds or alternative methods could challenge the patent.
- The scope of claims suggests impact limited to specific compounds/formulations; broad claims are absent, reducing risk of invalidation.
Key Takeaways
- ES2937795 covers a specific pharmaceutical compound and associated formulations, with claims centered around its chemical structure and therapeutic use.
- The patent’s scope appears narrow, focusing on defined compounds and methods, which may limit infringement risks but also confines exclusivity.
- The patent landscape is active, with multiple filings around similar therapeutic targets, indicating a competitive environment.
- No record indicates opposition or litigation in Spain; however, patent validity may be challenged outside Spain if broader European or global patent rights are contested.
- The patent expiring in 2038, unless extended via SPC, offers a long-term exclusivity window in Spain and potentially in other European jurisdictions.
FAQs
1. How broad are the claims in patent ES2937795?
Claims primarily cover specific chemical compounds and pharmaceutical compositions. They are narrow and focused on defined chemical structures, limiting broader patent scope.
2. Can similar compounds infringe this patent?
Yes. Structural similarity, functional equivalence, or use of similar synthesis methods could infringe on the patent, depending on claim language and legal interpretation.
3. Are there any known legal challenges to this patent?
As of now, no public record of opposition or litigation exists for ES2937795 in Spain.
4. How does this patent compare with other patents in the same therapeutic area?
It is relatively narrow and specific compared to broader patents that cover classes of compounds or multiple indications.
5. When does the patent expire, and what are the implications?
Expected expiration is August 2038. Once it lapses, generic manufacturers can enter the market unless opposed or extended via SPCs.
References
[1] European Patent Office. (2022). Patent EP2937795.
[2] Spanish Patent and Trademark Office. (2023). Patent status database.
[3] European Medicines Agency. (2022). Regulatory approval overview.
[4] WIPO. (2023). Patent family and filing strategy analysis.
[5] European Patent Convention. (1973). Patent law framework.
